Chengdu Kanghua Biological Products Co., Ltd. (hereinafter referredas “Kangh”) ,established in 2004, is one of the 13 enterprises with full vaccine production capacity in Chengdu Economic and Technological Development Zone, covering an area of 30000 square meters.Kangh is equipped with the world-class biotechnology experimental center, SPF experimental animal center, high-tech GMP production workshop for bacterial and viral vaccines. Its main business includes research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine ( human diploid cell) for Human Use, freeze-dried - HDCV.

Since its foundation, Kangh has been awarded the honor of “Post-Doctoral Innovation Practice Base”,"Innovative Enterprise"and “Sichuan Provincial Creditable Enterprise” by the government, and has passed GMP certification by the National Medical Products Administration. In recent years, Kanghhas undertaken several scientific and technological projects, and more than 100 technologies have applied for patent protection.

Kangh actively absorbs highly educated talent, at present, 80 % of the total number of employees have college degree or above. Most R&D personnel have more than 5 years of experience in the biological products industry. It possesses strong scientific research and development capabilities with comprehensive analysis, testing and experimental facilities, including more than 300 sets of production and research equipment, more than 100 inspection equipment, which can completely meet the needs of large-scale production and product quality requirements.

A number of research and development projects of the company were supported by the government special fund for science and technology. As the first self-developed and marketed product, “Group ACYW135 Meningococcal Polysaccharide Vaccine” won a good reputation among customers with its international first-class quality and has been exported overseas, laying a foundation for Kangh to establish a high-quality brand image. “Rabies Vaccine (human diploid cell) for Human Use, freeze-dried”, was launched in 2014, changing the zero production and sales history of it in China before, and is expected to contribute to the prevention and control of rabies in China and Asia. The seasonal influenza vaccine without preservatives has completed phase III clinical trials, and the human H5N1 Influenza Vaccine（Split Virion）was also completed pre-clinical studies and obtained approval for clinical trials to prepare for large-scale production. In addition, Kangh has four items under development, including the Freeze-dried Rabies Vaccine (human diploid cell, cultured by fixed bioreactor) for Human Use